Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kythera Biopharmaceuticals, a biotechnology company has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a pharmaceutical formulation patent application that covers ATX-101.
Subscribe to our email newsletter
ATX-101, an injectable drug being studied for the reduction of localized fat is a proprietary formulation of deoxycholate, an endogenous compound that is present in the body to promote the natural breakdown of dietary fat.
The patent application is titled ‘Formulations of Deoxycholic Acid and Salts Thereof.’
Kythera president and CEO Keith Leonard said the move was a key addition to their existing patent portfolio and would enforce their development efforts of ATX-101.
"We are focused on building on our strong patent protection as we further investigate the long-term safety and efficacy profile of ATX-101," Leonard added.